April 28, 2020 / 12:23 PM / a month ago

BRIEF-Onvansertib Trial In KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across Kras Mutation Subtypes And Durable Response

April 28 (Reuters) - Trovagene Inc:

* ONVANSERTIB TRIAL IN KRAS-MUTATED COLORECTAL CANCER DEMONSTRATES CONSISTENT TUMOR REGRESSION ACROSS KRAS MUTATION SUBTYPES AND DURABLE RESPONSE

* TROVAGENE INC - IN PHASE 1B DOSE ESCALATION, 1ST TWO DOSE LEVELS (ONVANSERTIB 12 MG/M(2 )AND 15 MG/M(2)) HAVE BEEN CLEARED FOR SAFETY

* TROVAGENE INC - 3RD DOSE LEVEL (ONVANSERTIB 18 MG/M(2)) IS ENROLLING; MAXIMUM TOLERATED DOSE HAS NOT BEEN REACHED TO-DATE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below